decoration green curve

Therapeutic platform

“Transforming a human first, data-driven microbiome discovery platform to drug development for multiple diseases” 

G-NiiB GenieBiome leverages one of the first and largest Asian human microbial data-driven approach to therapeutics development. Our expanding disease-specific microbial datasets compared with a comprehensive control microbial dataset provide a rich source for novel therapeutic candidates. We have the ability to develop novel consortia with beneficial functional and metabolic profiles, to target multiple human diseases.

Turning microbes into novel therapeutics 

Our Targeted Microbiome Supplements

were derived utilizing large metagenomic microbial datasets and machine-learning approaches to deliver missing microbes and their biologically important functions to restore “dysbiosis” in conditions associated with it.

Our
Technology Breakthrough 

Our unique Asian human microbiome database, advanced metagenomic sequencing technology and AI-driven data analysis platform enable us to analyse and develop unique, novel microbiome precision therapeutics. With our proprietary techniques, we have isolated over 20 novel live bacteria strains with therapeutically active functions. 

Explore More

Evidence-based therapeutics solutions 

Five unique microbiome formulas have been developed by using metagenomic sequencing data and proprietary AI and supported with data from clinical studies from the Faculty of Medicine, The Chinese University of Hong Kong.

Oral live microencapsulated bacteria for immunity- SIM01
Precise 3+3 Bifidobacteria and Prebiotics Formula with x? patents
Oral live microencapsulated bacteria for gut protection - SMT04
Precise Probiotics and prebiotics formula with 4 patents
Immune Kids Formula - SIM03
Precise probiotics and prebiotics with extra nutrition intensifiers with x patent
References
Wong MCS, Zhang L, Ching JYL, Mak JWY, Huang J, Wang S, Mok CKP, Wong A, Chiu OL, Fung YT, Cheong PK, Tun HM, Ng SC, Chan FKL. Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study). Nutrients. 2023 Apr 20;15(8):1982. doi: 10.3390/nu15081982. PMID: 37111201; PMCID: PMC10143994.